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Calcium carbonate is a porous inorganic nanomaterial with huge potential in biomedical 
applications and controlled drug delivery. This study aimed at evaluating the 
physicochemical properties and in vitro efficacy and safety of cockle shell aragonite calcium 
carbonate nanocrystals (ANC) as a potential therapeutic and hormonal delivery vehicle for 
osteoporosis management. Free and human recombinant parathyroid hormone 1-34 (PTH 1-
34)-loaded cockle shell aragonite calcium carbonate nanocrystals (PTH-ANC) were 
synthesized and evaluated using standard procedures. Transmission electron microscopy and 
field emission scanning electron microscopy results demonstrated highly homogenized 
spherical-shaped aragonite nanocrystals of 30±5 nm diameter. PTH-ANC had a zeta potential 
of −27.6 ± 8.9 mV. The encapsulation efficiency of the formulation was found to be directly 
proportional to the concentrations of the drug fed. The X-ray diffraction patterns revealed 
strong crystallizations with no positional change of peaks before and after PTH-ANC 
synthesis. Fourier transform infrared spectroscopy demonstrated no detectable interactions 
between micron-sized aragonite and surfactant at molecular level. PTH-ANC formulation 
was stabilized at pH 7.5, enabling sustained slow release of PTH 1-34 for 168 h (1 week). A 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cytocompatibility assay in 
Human Foetal Osteoblast Cell Line hFOB 1.19 showed that ANC can safely support 
osteoblast proliferation up to 48 h whereas PTH-ANC can safely support the proliferation at 
72 h and beyond due to the sustained slow release of PTH 1-34. It was concluded that due to 
its biogenic nature, ANC is a cytocompatible antiosteoporotic agent. It doubles as a 
nanocarrier for the enhancement of efficacy and safety of the bone anabolic PTH 1-34. ANC 
is expected to reduce the cost, dosage, and dose frequency associated with the use of PTH 1-
34 management of primary and secondary forms of osteoporosis. 
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